Refine
Institute
-
Cognitive behavioural therapy versus supportive therapy for persistent positive symptoms in psychotic disorders: the POSITIVE Study, a multicenter, prospective, single-blind, randomised controlled clinical trial
(2010)
- Background: It has been demonstrated that cognitive behavioural therapy (CBT) has a moderate effect on symptom reduction and on general well being of patients suffering from psychosis. However, questions regarding the specific efficacy of CBT, the treatment safety, the cost-effectiveness, and the moderators and mediators of treatment effects are still a major issue. The major objective of this trial is to investigate whether CBT is specifically efficacious in reducing positive symptoms when compared with non-specific supportive therapy (ST) which does not implement CBT-techniques but provides comparable therapeutic attention. Methods: The POSITIVE study is a multicenter, prospective, single-blind, parallel group, randomised clinical trial, comparing CBT and ST with respect to the efficacy in reducing positive symptoms in psychotic disorders. CBT as well as ST consist of 20 sessions altogether, 165 participants receiving CBT and 165 participants receiving ST. Major methodological aspects of the study are systematic recruitment, explicit inclusion criteria, reliability checks of assessments with control for rater shift, analysis by intention to treat, data management using remote data entry, measures of quality assurance (e.g. on-site monitoring with source data verification, regular query process), advanced statistical analysis, manualized treatment, checks of adherence and competence of therapists. Research relating the psychotherapy process with outcome, neurobiological research addressing basic questions of delusion formation using fMRI and neuropsychological assessment and treatment research investigating adaptations of CBT for adolescents is combined in this network. Problems of transfer into routine clinical care will be identified and addressed by a project focusing on cost efficiency. Discussion: This clinical trial is part of efforts to intensify psychotherapy research in the field of psychosis in Germany, to contribute to the international discussion on psychotherapy in psychotic disorders, and to help implement psychotherapy in routine care. Furthermore, the study will allow drawing conclusions about the mediators of treatment effects of CBT of psychotic disorders. Trial Registration Current Controlled Trials ISRCTN29242879
-
Buchbesprechungen aus Botanik und Naturschutz in Hessen Bd. 20
(2007)
- Folgende Publikationen werden rezensiert: Garve & al.: Verbreitungsatlas Niedersachsen, Hölzel & al.: Stromtalwiesen, Lübcke & Frede: Naturschutzgebiete in Hessen Band 4, Notizbuch 68 der Kasseler Schule, Riecken & al.: Rote Liste Biotoptypen, Schulz & Dengler: Verbreitungsatlas Moose Schleswig-Holstein, Szabo: Wandern – Erkennen – Heilen
-
Aquatische Makrophyten der Altarme von Rhein und Main in Hessen
(2010)
- Zur Schließung von Kenntnislücken zur Flora der Gewässer Hessens wurden 2009 von der BVNH neun Altarme von Rhein und Main untersucht. Die Ergeb-nisse zeigen, dass viele als sehr selten oder verschollen geltende Gewässermakrophyten noch oder wieder in den Altarmen des hessischen Oberrheinabschnitts zu finden sind. Insgesamt wurden 51 Arten nachgewiesen, darunter fünf Armleuchteralgen.
-
Buchbesprechungen aus Botanik und Naturschutz in Hessen Bd. 22
(2009)
- Folgende Publikationen werden rezensiert: Bushart & Suck: PNV Thüringens [als Broschüre / CD], Buttler & Hand: Florenliste, Dierschke & Briemle: Kulturgrasland, Dierßen & Dierßen: Moore, Godet: Knospen und Zweige, Godet: Bäume und Sträucher, Härdtle & al.: Wälder Tiefland und Mittelgebirge, Korsch & al.: Characeen Deutschlands, Kretzschmar: Orchideen Deutschlands, Mütterlein: Elevationseffekt, Ottich & al.: Stadtnatur Frankfurt, Pott & Remy: Gewässer Binnenland, Weber: Gebüsche, Hecken, Krautsäume, Wittig: Siedlungsvegetation, Wittig & al.: Flora Hoher Taunus.
-
Aquatische Makrophyten in hessischen Stillgewässern
(2009)
- Im Rahmen einer hessenweiten Untersuchung wurden etwa 70 künstliche Stillgewässer – Kiesgruben, Tagebaurestseen, Fischteiche – auf das Vorkommen von Wasserpflanzen untersucht. Die Untersuchung erbrachte den Nachweis von 78 Taxa, darunter 59 Arten Höherer Pflanzen und 19 Arten Characeen. Rund 25 % der nachgewiesnen Arten sind in der Roten Liste des Landes Hessen aufgeführt. Einige der nachgewiesenen Arten galten als verschollen. Von herausragender Bedeutung sind Kiesgruben in der Untermain- und Oberrhein-ebene, wo bis zu 10 Characeen-Arten in einem Gewässer nachgewiesen werden konnten. Von bundesweiter Bedeutung sind Funde von Nitella confervacea, N. tenuissima, Tolypella glomerata, T. intricata und T. prolifera. Als weit häufiger als erwartet erwies sich Potamogeton trichoides, die in allen Untersuchungsbereichen festgestellt wurde. Elodea nuttallii ist in den untersuchten Gewässern deutlich häufiger als E. canadensis. Sehr stark als Vogelrastplatz genutzte Teiche in der Wetterau zeigen, offenbar bedingt durch den Nährstoffeintrag durch Wasservögel, eine deutliche Eutrophierung.
-
Die Felsen-Zwenke (Brachypodium rupestre) in Hessen
(2007)
- Aus Hessen war Brachypodium rupestre bisher nur von einem Fundort veröffentlicht. Durch gezielte Suche und einen Zufallsfund kamen in den letzten Jahren fünf weitere hinzu. Die Wuchsorte sind anthropogene Böschungen von Straßen und Hochwasserrückhaltebecken, nur in einem Fall wachsen die Pflanzen auf einem naturnahen Standort in einer extensiv bewirtschafteten Stromtalwiese. Die Vorkommen gehen wahrscheinlich alle auf Ansaat zurück, entweder auf direkte Ansaat am Wuchsort oder ausgehend von den Primärpopulationen auf Verdriftung der Diasporen mit Hochwässern. Die Art ist in Hessen als eingebürgerter Neophyt einzustufen.
-
cGMP-dependent signaling pathways in spinal pain processing
(2009)
- Oral presentation from 4th International Conference of cGMP Generators, Effectors and Therapeutic Implications ; Regensburg, Germany. 19–21 June 2009 Background: An exaggerated pain sensitivity is the dominant feature of inflammatory and neuropathic pain both in the clinical setting and in experimental animal models. It manifests as pain in response to normally innocuous stimuli (allodynia), increased response to noxious stimuli (hyperalgesia) or spontaneous pain, and can persist long after the initial injury is resolved. Research over the last decades has revealed that several signaling pathways in the spinal cord essentially contribute to the pain sensitization. To test the contribution of cGMP produced by NO-sensitive guanylyl cyclase (NO-GC) to pain sensitization, we investigated the localization of NO-GC in the spinal cord and in dorsal root ganglia, and we characterized the nociceptive behavior of mice deficient in NO-GC (GC-KO mice). Results: We show that NO-GC (β1 subunit) is distinctly expressed in neurons of the mouse spinal cord, while its distribution in dorsal root ganglia is restricted to non-neuronal cells. GC-KO mice exhibited a considerably reduced nociceptive behavior in models of inflammatory or neuropathic pain, but their responses to acute pain were not impaired. Moreover, GC-KO mice failed to develop pain sensitization induced by spinal administration of drugs releasing NO. Surprisingly, during spinal nociceptive processing cGMP produced by NO-GC may activate signaling pathways different from cGMP-dependent protein kinase I (cGKI), while cGKI can be activated by natriuretic peptide receptor-B (NPR-B) dependent cGMP production. Conclusion: Taken together, our results provide evidence that NO-GC has a dominant role in the development of exaggerated pain sensitivity during inflammatory and neuropathic pain. Furthermore, beside the NO-mediated cGMP synthesis, cGMP produced by NPR-B contributes to pain sensitization by activation of cGKI.
-
Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID)
(2011)
- Introduction Evidence from a number of open-label, uncontrolled studies has suggested that rituximab may benefit patients with autoimmune diseases who are refractory to standard of care. The objective of this study was to evaluate the safety and clinical outcomes of rituximab in several standard of care-refractory autoimmune diseases (within rheumatology, nephrology, dermatology and neurology) other than rheumatoid arthritis or non-Hodgkin's lymphoma in a real-life clinical setting. Methods Patients who received rituximab having shown an inadequate response to standard of care had their safety and clinical outcomes data retrospectively analysed as part of the German Registry of Autoimmune Diseases. The main outcome measures were safety and clinical response, as judged at the discretion of the investigators. Results A total of 370 patients (299 patient-years) with various autoimmune diseases (23.0% with systemic lupus erythematosus, 15.7% antineutrophil cytoplasmic antibody-associated vasculitides, 15.1% multiple sclerosis and 10.0% pemphigus) from 42 centres received a mean dose of 2440 mg of rituximab over a median (range) of 194 (180 to 1407) days. The overall rate of serious infections was 5.3 per 100 patient-years during rituximab therapy. Opportunistic infections were infrequent across the whole study population, and mostly occurred in patients with systemic lupus erythematosus. There were 11 deaths (3.0% of patients) after rituximab treatment (mean 11.6 months after first infusion, range 0.8 to 31.3 months), with most of the deaths caused by infections. Overall (n = 293), 13.3% of patients showed no response, 45.1% showed a partial response and 41.6% showed a complete response. Responses were also reflected by reduced use of glucocorticoids and various immunosuppressives during rituximab therapy and follow-up compared with before rituximab. Rituximab generally had a positive effect on patient well-being (physician's visual analogue scale; mean improvement from baseline of 12.1 mm). Conclusions Data from this registry indicate that rituximab is a commonly employed, well-tolerated therapy with potential beneficial effects in standard of care-refractory autoimmune diseases, and support the results from other open-label, uncontrolled studies. Additional file 1: Supplemental tables. Table A1. Duration of follow-up from first rituximab infusion to last control visit by diagnosis. Table A2. Number of rituximab infusions by diagnosis.
-
Phosphorylation of Vasodilator-Stimulated Phosphoprotein (VASP) dampens hepatic ischemia-reperfusion injury
(2011)
- Recent work has demonstrated that the formation of platelet neutrophil complexes (PNCs) affects inflammatory tissue injury. Vasodilator-stimulated phosphoprotein (VASP) is crucially involved into the control of PNC formation and myocardial reperfusion injury. Given the clinical importance of hepatic IR injury we pursued the role of VASP during hepatic ischemia followed by reperfusion. We report here that VASP−/− animals demonstrate reduced hepatic IR injury compared to wildtype (WT) controls. This correlated with serum levels of lactate dehydrogenase (LDH), aspartate (AST) and alanine (ALT) aminotransferase and the presence of PNCs within ischemic hepatic tissue and could be confirmed using repression of VASP through siRNA. In studies employing bone marrow chimeric mice we identified hematopoietic VASP to be of crucial importance for the extent of hepatic injury. Phosphorylation of VASP on Ser153 through Prostaglandin E1 or on Ser235 through atrial natriuretic peptide resulted in a significant reduction of hepatic IR injury. This was associated with a reduced presence of PNCs in ischemic hepatic tissue. Taken together, these studies identified VASP and VASP phosphorylation as crucial target for future hepatoprotective strategies.
